Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 6/20 | 0.63 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.63 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.63 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.63 |
| ▸ | MET | P08581 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15815661 | 0.88 | MET (0.57) | PDE4APDE4BPDE4CPDE4DMET | |
| SCHEMBL15815769 | 0.81 | PDE4B (0.54) | PDE4APDE4BPDE4CPDE4DMET | |
| SCHEMBL15815815 | 0.77 | ACHE (0.49) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL15815327 | 0.75 | PDE4B (0.64) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL16144681 | 0.73 | PDE4A (0.50) | PDE4APDE4BPDE4CPDE4DMET | |
| SCHEMBL10417279 | 0.70 | ABCB11 (0.69) | ALDH1A1MAPTHTTHPGDSMN1; SMN2 | |
| SCHEMBL15836998 | 0.70 | MET (0.53) | PDE4APDE4BPDE4CPDE4DMET | |
| SCHEMBL107604 | 0.69 | MET (0.50) | PDE4APDE4BPDE4CPDE4DMET | |
| SCHEMBL16144707 | 0.68 | PDE4A (0.44) | PDE4APDE4BPDE4CPDE4DMET | |
| SCHEMBL15815194 | 0.68 | MET (0.52) | PDE4APDE4BPDE4CPDE4DMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160130228-A1 | Novel Heterocyclic Compounds as Bromodomain Inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2016-05-12 | — | — | US | claimed |
| EP-2935253-A2 | NOVEL HETEROCYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | Zenith Epigenetics Corp. (CA) | 2015-10-28 | — | — | EP | claimed |
| US-20140179648-A1 | Novel Heterocyclic Compounds as Bromodomain Inhibitors | RVX THERAPEUTICS INC. (CA) | 2014-06-26 | — | — | US | claimed |
| WO-2014096965-A2 | NOVEL HETEROCYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | RVX THERAPEUTICS INC. (CA) | 2014-06-26 | — | — | WO | claimed |
| EP-2935253-B1 | NOVEL HETEROCYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS LTD (CA) | 2018-08-01 | — | — | EP | disclosed |
| US-9861637-B2 | Heterocyclic compounds as bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2018-01-09 | — | — | US | disclosed |
| US-9861637-B2 | Heterocyclic compounds as bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2018-01-09 | — | — | US | disclosed |
| US-20170143731-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS LTD. | 2017-05-25 | — | — | US | disclosed |
| US-20170143731-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS LTD. | 2017-05-25 | — | — | US | disclosed |
| US-20170143731-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS LTD. | 2017-05-25 | — | — | US | disclosed |
| US-9598367-B2 | Heterocyclic compounds as bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2017-03-21 | — | — | US | disclosed |
| US-9598367-B2 | Heterocyclic compounds as bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2017-03-21 | — | — | US | disclosed |
| US-9271978-B2 | Heterocyclic compounds as bromodomain inhibitors | ZENITH EPIGENETICS CORP. (CA) | 2016-03-01 | — | — | US | disclosed |
| US-9271978-B2 | Heterocyclic compounds as bromodomain inhibitors | ZENITH EPIGENETICS CORP. (CA) | 2016-03-01 | — | — | US | disclosed |
| US-9271978-B2 | Heterocyclic compounds as bromodomain inhibitors | ZENITH EPIGENETICS CORP. (CA) | 2016-03-01 | — | — | US | disclosed |
| EP-2935253-A2 | NOVEL HETEROCYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | Zenith Epigenetics Corp. (CA) | 2015-10-28 | — | — | EP | disclosed |
| US-20140179648-A1 | Novel Heterocyclic Compounds as Bromodomain Inhibitors | RVX THERAPEUTICS INC. (CA) | 2014-06-26 | — | — | US | disclosed |
| US-20140179648-A1 | Novel Heterocyclic Compounds as Bromodomain Inhibitors | RVX THERAPEUTICS INC. (CA) | 2014-06-26 | — | — | US | disclosed |
| US-20140179648-A1 | Novel Heterocyclic Compounds as Bromodomain Inhibitors | RVX THERAPEUTICS INC. (CA) | 2014-06-26 | — | — | US | disclosed |
| WO-2014096965-A2 | NOVEL HETEROCYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | RVX THERAPEUTICS INC. (CA) | 2014-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160130228-A1 | Novel Heterocyclic Compounds as Bromodomain Inhibitors | BRD4, BRDT, BRD3 | PDE4A 2500/4885PDE4B 2267/4885PDE4C 2241/4885 |
| US-20170143731-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | BRD4, BRDT, BRD3 | PDE4A 2500/4885PDE4B 2267/4885PDE4C 2241/4885 |
| US-20140179648-A1 | Novel Heterocyclic Compounds as Bromodomain Inhibitors | BRD4, BRDT, BRD3 | PDE4A 2500/4885PDE4B 2267/4885PDE4C 2241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.